The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time

PURPOSE: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used for the treatment of advanced estrogen receptor (ER)-positive breast cancer. To develop a treatment strategy for cancers resistant to CDK4/6 inhibitors, here, we established palbociclib-resistant sublines and analyzed their...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Mayu, Oba, Takaaki, Shibata, Tomohiro, Ito, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484193/
https://www.ncbi.nlm.nih.gov/pubmed/34244855
http://dx.doi.org/10.1007/s00432-021-03722-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484193/
https://www.ncbi.nlm.nih.gov/pubmed/34244855
http://dx.doi.org/10.1007/s00432-021-03722-3

Ejemplares similares